Posted by Michael Wonder on 23 Oct 2023
1 November 2023 changes to the PBS listings of medicines for severe active rheumatoid arthritis
23 October 2023 - On 1 November 2023, changes will be made to the authority requirements of the following biological and immunomodulator medicines listed on the PBS for the treatment of rheumatoid arthritis – adalimumab, abatacept, baricitinib, certolizumab, etanercept, golimumab, infliximab, tocilizumab and tofacitinib.
From this date, the PBS listings of biosimilar medicines for initial therapy will change from Authority Required (Written), to Authority Required (Telephone/Immediate online assessment). The PBS listings of biosimilar medicines for first continuing therapy will change to Authority Required (Streamlined).,
